|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...93949596979899100101102103...110111» |
- Clinical: Computer-Assisted Self-Interviews and Health Screening in the Pediatric Emergency Department (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=801, Completed, Sponsor: Washington University School of Medicine
- Enrollment change: Alternate Dosing Schedules Study for HPV Vaccine (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=333, Completed, Sponsor: Duke University
N=750 --> 333
- Trial completion: Alternate Dosing Schedules Study for HPV Vaccine (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=333, Completed, Sponsor: Duke University
N=750 --> 333 Recruiting --> Completed
- Enrollment change: Prospective Observational Study of Peri-implantation Serum hCG Levels (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=451, Completed, Sponsor: Bruce Shapiro M.D.
Recruiting --> Completed N=300 --> 451
- Trial completion: Prospective Observational Study of Peri-implantation Serum hCG Levels (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=451, Completed, Sponsor: Bruce Shapiro M.D.
N=300 --> 451 Recruiting --> Completed
- Trial completion: Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=332, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
New P1/2 trial: Myocet (clinicaltrials.gov) - Oct 10, 2012
P1/2, N=88, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
- |||||||||| Entereg (alvimopan) / Merck (MSD)
New P3 trial, Surgery: Accelerating Gastrointestinal Recovery (clinicaltrials.gov) - Oct 9, 2012
P3, N=134, Recruiting, Sponsor: Jamie N. Bakkum-Gamez
- Enrollment closed: Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=160, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion: A Comparison of Two Freezing Techniques (clinicaltrials.gov) - Oct 7, 2012
P=N/A, N=18, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Emestop (ramosetron hydrochloride) / Samyang Group
Trial completion, CINV: Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (clinicaltrials.gov) - Oct 7, 2012
P2, N=89, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- |||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov) - Oct 4, 2012
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Trial termination, IO biomarker: ChemoFx® PRO - A Post-Market Data Collection Study (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=2756, Terminated, Sponsor: Precision Therapeutics
Active, not recruiting --> Completed Recruiting --> Terminated
- Trial termination: Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=256, Terminated, Sponsor: Precision Therapeutics
Recruiting --> Terminated Active, not recruiting --> Terminated
- topotecan / Generic mfg., erlotinib / Generic mfg.
Enrollment change: Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer (clinicaltrials.gov) - Oct 3, 2012
P2, N=6, Terminated, Sponsor: New York University School of Medicine
Active, not recruiting --> Terminated N=30 --> 6
- ||| ombrabulin (AVE8062) / Sanofi
Enrollment closed: OPSALIN: Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (clinicaltrials.gov) - Oct 3, 2012
P2, N=150, Active, not recruiting, Sponsor: Sanofi
N=30 --> 6 Recruiting --> Active, not recruiting
- Trial withdrawal, IO biomarker: Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Suspended --> Withdrawn
- Enrollment change, IO biomarker: Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Suspended --> Withdrawn N=36 --> 0
- paclitaxel / Generic mfg.
Trial completion: S9912 Combination Chemo in Stage III Ovarian Cancer, (clinicaltrials.gov) - Oct 2, 2012
P2, N=68, Completed, Sponsor: Southwest Oncology Group
N=36 --> 0 Active, not recruiting --> Completed
- Trial termination: Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=65, Terminated, Sponsor: Institut Universitari Dexeus
Active, not recruiting --> Completed Recruiting --> Terminated; Due to the high number of multiples pregnancies in the double embryo transfer group, we have decided to stop the enrollment of patients at 07/31/2012
- Enrollment change: Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=65, Terminated, Sponsor: Institut Universitari Dexeus
Recruiting --> Terminated; Due to the high number of multiples pregnancies in the double embryo transfer group, we have decided to stop the enrollment of patients at 07/31/2012 N=160 --> 65
- | Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial completion: Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer (clinicaltrials.gov) - Oct 1, 2012
P2, N=41, Completed, Sponsor: Neovii Biotech
N=160 --> 65 Active, not recruiting --> Completed
- |||||||||| Visanne (dienogest) / Mochida, Bayer
New P3 trial: Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis (clinicaltrials.gov) - Sep 30, 2012
P3, N=312, Active, not recruiting, Sponsor: Bayer
- | New P2 trial: ProVIP: Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy (clinicaltrials.gov) - Sep 30, 2012
P2, N=86, Completed, Sponsor: Mount Sinai Hospital, Canada
- clomifene citrate / Generic mfg.
Trial completion: Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=174, Completed, Sponsor: Mansoura Integrated Fertility Center
Active, not recruiting --> Completed Recruiting --> Completed
- etonogestrel/ethinylestradiol intravaginal ring / Generic mfg.
Trial termination: NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=70, Terminated, Sponsor: University of Toronto
Recruiting --> Completed Completed --> Terminated
- |||||| Zorbtive (somatropin) / EMD Serono
Enrollment open: EMR701173_002: Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women (clinicaltrials.gov) - Sep 27, 2012
P3, N=87, Recruiting, Sponsor: Merck KGaA
Completed --> Terminated Not yet recruiting --> Recruiting
- Trial initiation date: Implementation of an Efficacious Intervention for High Risk Women in Mexico (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=1080, Recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Initiation date: Jan 2011 --> Nov 2011
- Trial initiation date: Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=400, Active, not recruiting, Sponsor: University of California, San Diego
Initiation date: Jan 2011 --> Nov 2011 Initiation date: Jul 2010 --> Jan 2011
- Enrollment change, Surgery: The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=100, Completed, Sponsor: Samsung Medical Center
Initiation date: Jul 2010 --> Jan 2011 N=135 --> 100
- |||||||||| New P3 trial: LVS-20: Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding (clinicaltrials.gov) - Sep 26, 2012
P3, N=280, Completed, Sponsor: Uteron Pharma S.A.
- Trial completion, Surgery: The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=100, Completed, Sponsor: Samsung Medical Center
N=135 --> 100 Recruiting --> Completed
- methamphetamine / Generic mfg.
Trial initiation date: Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users (clinicaltrials.gov) - Sep 26, 2012
P2, N=429, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed Initiation date: Sep 2006 --> Feb 2007
- tranexamic acid oral / Generic mfg.
Enrollment change: Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=30, Active, not recruiting, Sponsor: Baylor College of Medicine
Initiation date: Sep 2006 --> Feb 2007 N=24 --> 30
- methamphetamine / Generic mfg.
Trial completion: Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users (clinicaltrials.gov) - Sep 26, 2012
P2, N=429, Completed, Sponsor: University of California, San Diego
N=24 --> 30 Active, not recruiting --> Completed
- methamphetamine / Generic mfg.
Trial completion: STD Risk Reduction for Heterosexual Methamphetamine Users (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=432, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=3900, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=494, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma
Enrollment open, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 25, 2012
P1, N=18, Recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=20, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Parents Matter!: Interventions to Promote Effective Parent-Child Communication (clinicaltrials.gov) - Sep 25, 2012
P1, N=2210, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=45000, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: The Association of G9a Protein and Outcome of Patients With Endometrial Cancer (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=97, Completed, Sponsor: Far Eastern Memorial Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- metformin / Generic mfg., letrozole / Generic mfg.
New P1 trial: Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Sep 24, 2012
P1, N=146, Completed, Sponsor: Zagazig University
- Trial termination, Minimal residual disease: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=3, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Active, not recruiting --> Terminated; Low accrual
- |||| Trial completion: Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia (clinicaltrials.gov) - Sep 20, 2012
P4, N=204, Completed, Sponsor: Bayer
Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed
- ||||| veliparib (ABT-888) / AbbVie
New P1/2 trial, BRCA Biomarker: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status (clinicaltrials.gov) - Sep 20, 2012
P1/2, N=80, Recruiting, Sponsor: Vejle Hospital
- carboplatin / Generic mfg., cisplatin / Generic mfg.
Trial termination, Surgery: Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=38, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=141, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=312 --> 141
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=312 --> 141 N=44 --> 132